BIOMERIEUX SA financials
BIOMERIEUX SA
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
549300AK8Y0LBIQ4T071 Financial statements
(EUR, as reported — unscaled; 97 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €4.07B | €3.98B |
| Cost of sales | €1.76B | €1.76B |
| Gross profit | €2.31B | €2.22B |
| Distribution costs | €791.2M | €783.8M |
| Operating profit (EBIT) | €521.3M | €588.8M |
| Income tax expense | €128.8M | €154.3M |
| Profit for the year | €396.9M | €425.1M |
| — attributable to owners | €397.5M | €432.2M |
| — attributable to NCI | -€600.0K | -€7.1M |
| Total comprehensive income | -€5.1M | €573.6M |
| Cash flow statement | ||
| Net cash from operating activities | €788.4M | €667.3M |
| Net cash from investing activities | -€461.7M | -€359.8M |
| Net cash from financing activities | -€155.4M | -€212.6M |
| Proceeds from borrowings | €33.6M | €9.8M |
| Repayments of borrowings | €63.2M | €84.6M |
| Net change in cash | €171.3M | €94.8M |
| Balance sheet | ||
| Total assets | €5.57B | €5.77B |
| Non-current assets | €3.03B | €3.27B |
| Property, plant & equipment | €1.52B | €1.53B |
| Right-of-use assets | €141.3M | €170.2M |
| Intangible assets & goodwill | €727.8M | €730.4M |
| Inventories | €959.7M | €1.04B |
| Cash & equivalents | €569.8M | €449.8M |
| Total equity | €4.11B | €4.21B |
| — attributable to owners | €4.10B | €4.20B |
| Non-controlling interests | €3.9M | €6.1M |
| Non-current liabilities | €404.0M | €424.1M |
| Deferred tax liabilities | €26.0M | €25.7M |
| Derived metrics | ||
| Free cash flow | €453.1M | €321.5M |
| Operating margin | 12.8% | 14.8% |
| Net margin | 9.8% | 10.7% |
| Return on equity | 9.7% | 10.1% |
| Cash conversion ratio | 1.99× | 1.57× |
| Capex coverage | 2.35× | 1.93× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€10.1M | -€85.1M |
| Adjustments For Decrease Increase In Other Operating Receivables | -€4.6M | -€3.7M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €438.4M | €325.1M |
| Adjustments For Fair Value Gains Losses | €1.2M | -€600.0K |
| Adjustments For Finance Income Cost | -€8.9M | -€4.5M |
| Adjustments For Income Tax Expense | €128.8M | €154.3M |
| Adjustments For Increase Decrease In Trade Account Payable | €3.4M | -€600.0K |
| Adjustments For Provisions | €14.4M | -€8.2M |
| Adjustments For Sharebased Payments | €26.5M | €23.4M |
| Adjustments For Undistributed Profits of Associates | -€100.0K | €0 |
| Basic Earnings Loss Per Share From Continuing Operations | €3.37 | €3.67 |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €565.1M | €442.1M |
| Comprehensive Income Attributable To Noncontrolling Interests | -€2.2M | -€6.9M |
| Comprehensive Income Attributable To Owners of Parent | -€3.0M | €580.5M |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €2.54B | €2.50B |
| Current Financial Liabilities | €131.4M | €141.5M |
| Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale | €1.06B | €1.13B |
| Current Provisions | €44.3M | €37.3M |
| Current Tax Assets | €47.8M | €21.3M |
| Current Tax Liabilities | €18.3M | €35.4M |
| Deferred Tax Assets | €108.1M | €145.9M |
| Diluted Earnings Loss Per Share From Continuing Operations | €3.34 | €3.64 |
| Dividends Paid Ordinary Shares Per Share | €0.90 | €0.85 |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €106.1M | €100.2M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€48.4M | €13.9M |
| Equity and Liabilities | €5.57B | €5.77B |
| General and Administrative Expense | €320.0M | €313.8M |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | €300.0K | €1.3M |
| Income Tax Relating To Investments In Equity Instruments of Other Comprehensive Income | €0 | -€100.0K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €1.3M | -€200.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €151.6M | €205.5M |
| Increase Decrease In Working Capital | €71.3M | €51.0M |
| Intangible Assets Other Than Goodwill | €401.5M | €492.0M |
| Investment Accounted For Using Equity Method | €700.0K | €800.0K |
| Issued Capital | €12.0M | €12.0M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | €0 | €0 |
| Noncurrent Finance Lease Receivables | €10.3M | €9.1M |
| Noncurrent Financial Assets | €128.7M | €195.0M |
| Noncurrent Financial Liabilities | €330.0M | €349.2M |
| Noncurrent Provisions | €48.0M | €49.2M |
| Other Adjustments To Reconcile Profit Loss | €38.3M | €14.8M |
| Other Comprehensive Income | -€402.0M | €148.5M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | €2.0M | €5.2M |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | -€39.3M | -€38.8M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €5.8M | -€1.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€368.9M | €183.9M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€367.2M | €187.9M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€34.8M | -€39.4M |
| Other Current Assets | €18.4M | €24.5M |
| Other Current Payables | €539.4M | €574.2M |
| Other Current Receivables | €178.5M | €176.0M |
| Other Finance Income Cost | -€8.9M | -€4.5M |
| Other Reserves | €1.61B | €1.26B |
| Payments From Changes In Ownership Interests In Subsidiaries | €1.5M | €0 |
| Payments To Acquire Or Redeem Entitys Shares | €18.2M | €37.6M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €10.4M | €9.4M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €335.3M | €345.8M |
| Research and Development Expense | €507.4M | €491.5M |
| Retained Earnings Profit Loss For Reporting Period | €397.5M | €432.2M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -€100.0K | €0 |
| Share Premium | €74.0M | €74.0M |
| Trade and Other Payables To Trade Suppliers | €262.1M | €272.4M |
Methodology
Every line item above is a fact tagged in BIOMERIEUX SA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.